Logo
Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome to ShareScene - Talk Shares And Take Stock With Australia's Sharemarket Community - New Here? Click To Register >

734 Pages (Click to Jump) V  < 1 2 3 4 5 6 > »    
 
  
Reply to this topic

BLT, BENITEC BIOPHARMA LIMITED
Pannobhaso
post Posted: May 24 2014, 02:29 PM
  Quote Post


Posts: 421
Thanks: 275


In Reply To: plastic's post @ May 24 2014, 08:18 AM

QUOTE
With the cutbacks in the recent budget, I can't see CSIRO being too keen to fulfil their responsibilities to pursue the appeal. Especially if there are no real bucks to be had at the end. Very different from the WiFi case. Over a billion dollars came back on that one.


Actually, what you have posted is not true but regular readers would not be surprised by that fact. The reason why Bayer objected to the patent and the reason why both the CSIRO and Bayer objected to the Galapagos patent EP1444346 was because of the implications for veterinary applications. There are likely to be a number commercialised veterinary ddRNAi products before the patent expires and these will be worth millions of dollars in royalties.

As Benitec has no interest in veterinary applications, this decision will have little impact on future revenue. Even if Benitec loses an appeal against the decision, royalties will only be paid when human ddRNAi products are commercialised in Europe and there won't be too many of them before the expiry of the patent. This is why the current management of Benitec are taking the company in a direction that does not rely on gatekeeper IP to generate revenue. The company will make its revenue from its pipeline, with IP that is specific to the ailments being treated. Also, any revenue lost in Europe (should an appeal fail) could be regained by Galapagos having to pay royalties in jurisdictions where its objections have failed, such as the UK and USA, should it commercialise any ddRNAi products.

If there are grounds for appeal, then I am sure that the CSIRO will lodge one. We also have to await the outcome of Bayer's objection to EP1444346.



--------------------
"It turns out Pannobhaso is right."
Plastic (Alias rubra)

Said 'Thanks' for this post: groucho  
 
plastic
post Posted: May 24 2014, 08:42 AM
  Quote Post


Posts: 5,891
Thanks: 183


QUOTE
RXi Pharmaceuticals granted US notice of allowance covering sd-rxRNA technology platform
"Published 23 May 2014 RXi Pharmaceuticals has announced that it received the notice of allowance from the US Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA).



The patent, titled 'Reduced Size Self-Delivering RNAi Compounds', broadly covers both the composition and methods of use of RXi's self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029.

This core patent, within RXi's intellectual property portfolio, is the foundation for RXI's self-delivering platform. The patent broadly protects RXi's sd-rxRNA technology, which facilitates the delivery of RNAi compounds to tissues and cells of interest in the absence of a delivery vehicle.

sd-rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. This allows sd-rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

RXi Pharmaceuticals president and CEO Dr Geert Cauwenbergh said that the company is pleased to have its novel technology recognized by the US Patent and Trademark Office.

"This key patent is what differentiates RXi's technology platform from the competition. It provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles, which are commonly used with the other siRNA compounds in clinical development. The use of our proprietary sd-rxRNA technology platform may lead to improved tolerability and thereby potentially broadening of the therapeutic window for these compounds," Dr Cauwenbergh added.






--------------------
Where are the Americans?
 
plastic
post Posted: May 24 2014, 08:18 AM
  Quote Post


Posts: 5,891
Thanks: 183


This patent award is interesting. For years and maybe even still now, the CEO of RXi was based in Wellington NZ with a plum job at the local university. Dirk and Kay have patented something similar but he never speaks of anything except SNALP and TKMR. Makes me wonder if he is on the level. Plus it happens right at the same time as BLT's patent gets knocked back. Are the two related?

Prosensa had over 12% of the company traded overnight with a 27% increase in price. In fact all gene therapy companies were stronger. This on the Friday before a long weekend in both the US and the UK at the end of May. Sell in May is over. The bottom has been hit. Looking forward to next week.

Meanwhile, the chinks in the BLT story of invincibility is beginning to show with the patent rejection in Europe. The counter party, Galapagos, were once in bed with MRK. MRK terminated their partnership, but have so far not taken another beyond antibodies scaffold partner to my knowledge. At least they haven't disclosed it. But I believe they are working with PYC on that count.

I guess the new funding BLT have found will now be used to pay for the patent appeal. With the cutbacks in the recent budget, I can't see CSIRO being too keen to fulfil their responsibilities to pursue the appeal. Especially if there are no real bucks to be had at the end. Very different from the WiFi case. Over a billion dollars came back on that one.

PF looking like not much more than a overpaid titular CEO only. Guess we could just say a tit instead.

Bring on the buy out.


</h1>[quote]<h1>RXi Pharmaceuticals granted US notice of allowance covering sd-rxRNA technology platform




--------------------
Where are the Americans?
 
diana
post Posted: May 23 2014, 12:21 PM
  Quote Post


Posts: 6,583
Thanks: 342


In Reply To: arty's post @ May 22 2014, 11:03 AM

You should be getting buckets of adulation arty, for your heads up on a very nice trade. rolleyes.gif

R/Di






--------------------
"Adversity does not build character; adversity reveals character."
Sandy Dahl
 
arty
post Posted: May 22 2014, 11:03 AM
  Quote Post


Posts: 11,995
Thanks: 2869


In Reply To: arty's post @ May 13 2014, 04:34 PM

QUOTE
The horizontal Beetroot-coloured line at $1.07 would become my entry level, with the falling resistance trendline forming the first resistance target.

Bingo! We made contact with the target and are now on the way back down. thumbdown.gif

Attached Image


BLT even made today's "Poor List" early on when the drop measured over 10%

Attached Image



--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 
Pannobhaso
post Posted: May 15 2014, 10:42 AM
  Quote Post


Posts: 421
Thanks: 275


In Reply To: plastic's post @ May 15 2014, 06:59 AM

If, as you claim, TT-034 is really the Regulus HCV treatment, then presumably you should be reading the "last rights", or even the last rites, to Regulus, your pet company. Either way, you have goofed again.



--------------------
"It turns out Pannobhaso is right."
Plastic (Alias rubra)

Said 'Thanks' for this post: joules mm1  Qld1  
 


plastic
post Posted: May 15 2014, 06:59 AM
  Quote Post


Posts: 5,891
Thanks: 183


So its like I say. On any level using any tool this thing is a dog.

Any expectation of trials changing anything is misguided as the trials are never going to be a goer...after more than ten years.

Most people would call that a corporate and scientific failure. Someone should read them their last rights.



--------------------
Where are the Americans?

Said 'Thanks' for this post: rubra  
 
diana
post Posted: May 13 2014, 09:31 PM
  Quote Post


Posts: 6,583
Thanks: 342


In Reply To: arty's post @ May 13 2014, 04:34 PM

Thanks arty. Were you by any chance hungry when you wrote that. They say you should never do supermarket shopping when you are hungry. rolleyes.gif

R/Di






--------------------
"Adversity does not build character; adversity reveals character."
Sandy Dahl
 
arty
post Posted: May 13 2014, 04:34 PM
  Quote Post


Posts: 11,995
Thanks: 2869


In Reply To: diana's post @ May 12 2014, 10:14 AM

Hello Di,
seeing you're more interested in the T/A side of things, let me pick up that thread (from Exoma)

The code BLT always makes me smile: We have green candles = Lettuce; red candles = Tomatoes; but the price trend looks very sorry indeed, so it's unlikely to bring home the ... Bacon, that's right smile.gif

Attached Image



On a more positive note though: The 1-year EMA line is yellow and has steadily run below the price candles. Specifically in December, price has touched, but not really cut below the Mustard. If the same remains true during the current touchy period, if the price stays above 90c support, then I can see a promising trade opportunity coming up. The horizontal Beetroot-coloured line at $1.07 would become my entry level, with the falling resistance trendline forming the first resistance target.

Failing that, however, there is still that open gap 72.5c - 75.5c, where your Big Mac might fall towards. The other two gaps have already been filled, which doesn't bode all that well for the little one to remain permanently open. It is however possible that the resistance trendline is tested first, the gap then closed a few months later.



--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 
 
 


734 Pages (Click to Jump) V  < 1 2 3 4 5 6 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareScene.com, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING